A Multicenter Clinical Trial: Efficacy, Safety of Fecal Microbiota Transplantation for Inflammatory Bowel Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are many limitations in the current treatments of Inflammatory bowel disease(IBD). Some patients have no or little reaction to the traditional drugs. Now the investigators realized that the intestinal microbiota is closely associated with the development of IBD. In recent years, a retrospective study showed that the overall efficiency of fecal microbiota transplantation (FMT) for IBD was 79%, the overall remission rate was 43%, which opened a new chapter in the treatment of IBD. So the standardized fecal microbiota transplantation is considered to be simple but effective emerging therapies for the treatment of IBD. In this project the investigators intend to carry out a single-center, randomized, single-blind clinical intervention study. The investigators plan to recruit patients with IBD (Ulcerative Colitis and Crohn's Disease) in China. The patients will be randomly divided into two groups, one group will be given treatment of standardized fecal microbiota transplantation, the other will be simply treated with traditional drugs, followed up for at least 1 year. The investigators aim to determine the efficiency, durability and safety of Fecal Microbiota Transplantation for IBD treatment, and further to explore which major microbiota may effect in this project.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Intestinal Microbiota Transplantation for Inflammatory Bowel Diseases

NCT03426683

Inflammatory Bowel Disease(IBD)

COMPLETED NA

Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing

NCT02998112

Ulcerative Colitis

UNKNOWN PHASE4

Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease

NCT02335281

Inflammatory Bowel Disease Ulcerative Colitis Crohn's Disease

UNKNOWN PHASE2

Standardized Fecal Microbiota Transplantation for Ulcerative Colitis

NCT01790061

Bacteria Microbiota Fecal Microbiota Transplantation +2 more

RECRUITING PHASE2/PHASE3

The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis

NCT02435160

Ulcerative Colitis Fecal Microbiota Transplantation

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this projects the investigators aim to re-establish a gut balance of intestinal microbiota through Standardized Fecal Microbiota Transplantation for IBD (UC and CD). We have established a standardized isolation, store, and transport steps of fecal bacteria from donated fresh stool in the laboratory. Then the bacteria will be transplanted to mid-gut by capsule. Patients in this study will be assigned to receive standardized FMT three times or not and would be followed up for at least 1 year. The clinical symptoms, sign, blood tests, endoscopy and questionnaire will be used to assess the efficiency, durability and safety of Standardized FMT at the start and end of the projects. At last, we will use 16S-rDNA to estimate the change of intestinal microbiota.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease, Ulcerative Colitis Type

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standardized FMT

The patients will receive standardized FMT. The FMT was given by capsule. It was given three times a week.

Group Type EXPERIMENTAL

fecal microbiota capsule

Intervention Type DRUG

a capsule full of fecal microbiota extracting from the health

Without FMT

The patients will receive FMT with blank capsule.

Group Type PLACEBO_COMPARATOR

fecal microbiota capsule

Intervention Type DRUG

a capsule full of fecal microbiota extracting from the health

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fecal microbiota capsule

a capsule full of fecal microbiota extracting from the health

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Standard or conventional medicine treatment ineffective of IBD patients
2. IBD patients with recurrent symptoms
3. IBD patients who had drug dependence or recurrence when reduced or discontinued use
4. Untreated IBD patients who voluntarily received FMT

Exclusion Criteria

1. IBD patients with contraindications for gastrointestinal endoscopy
2. IBD patients combined with other serious diseases such as respiratory failure, heart failure and severe immunodeficiency
3. IBD patients with indication of surgery

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes